News
Explore the growing GLP-1 agonists market, driven by rising diabetes and obesity rates. Discover advancements in therapies like Tirzepatide and GZR18, offering both glycemic control and weight loss ...
Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...
Researchers conducted a post hoc analysis of the SURMOUNT-1 trial to assess the effect of tirzepatide on kidney function in prediabetes with obesity or overweight.
Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...
New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...
Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...
A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with overweight or obesity, outperforming liraglutide and placebo. Brain ...
A higher proportion of sleep medicine providers vs. patients reported CPAP over tirzepatide as their preferred treatment option for comorbid obesity and obstructive sleep apnea, according to data ...
Tirzepatide has emerged as the most effective treatment for lowering blood sugar and promoting weight loss in people with ...
For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results